Tag: Skyclarys

In a significant development for the rare disease community, the FDA approved the first-ever treatment for Friedreich's ataxia in early 2023, offering a major breakthrough after years with no disease-specific drugs. This milestone, along with other promising therapies currently under review, provides a clearer answer to the question, "What is the new medicine for ataxia?" and fuels optimism for future treatments across various forms of this debilitating condition.

The name "Sky" is associated with a variety of substances, from FDA-approved prescription medications to extremely hazardous street drugs. Properly identifying **what kind of drug is Sky?** requires careful attention to context to avoid dangerous misunderstandings between clinical and recreational use.